Core Viewpoint - The stock of Giant Bio (02367) has dropped over 4%, halving from its year-to-date high of 85.79 HKD, currently trading at 39.22 HKD with a transaction volume of 745 million HKD [1] Group 1: Company Performance - The pre-sale performance of Giant Bio's subsidiary, Kefu Mei, during this year's "Double Eleven" event has been lackluster [1] - According to Citigroup's report, the main products of Giant Bio showed a decline in performance during the pre-sale on October 15 in Li Jiaqi's live stream [1] - Citigroup noted that the company's promotional strategy has become more stringent, making its pricing less attractive compared to other brands [1] Group 2: Market Reaction and Future Outlook - Citigroup believes that the market's reaction to the decline in pre-sale performance during the first day of Double Eleven is overblown [1] - Although sales trends from Li Jiaqi's live streaming are important indicators for Double Eleven performance, the contribution from this channel has significantly decreased due to the growth of other KOLs and the company's own live streaming efforts [1] - Despite the intense competition, there has been no negative feedback from customers regarding the company's products or brand [1] - Given the low base this year, Citigroup expects Giant Bio's sales to recover in the fiscal year 2026, and the company's valuation remains attractive [1]
巨子生物再跌超4% 可复美在双十一预售中表现平淡 花旗称市场反应过度